Detects feline CCL5/RANTES in ELISAs and Western blots. In sandwich immunoassays, less than 0.02% cross-reactivity with recombinant human RANTES, recombinant mouse RANTES, and recombinant cotton rat RANTES is observed.
Polyclonal Sheep IgG
E. coli-derived recombinant feline CCL5/RANTES Tyr26-Asn92 (Lys84Tyr and Gly85 del) Accession # Q8SQ40
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Recombinant Feline CCL5/RANTES Protein (Catalog #
Measured by its ability to neutralize CCL5/RANTES-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CCR5. The Neutralization Dose (ND50) is typically 0.5-2.5 µg/mL in the presence of 80 ng/mL Recombinant Feline CCL5/RANTES.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Chemotaxis Induced by CCL5/RANTES and Neutralization by Feline CCL5/ RANTES Antibody.
Recombinant Feline CCL5/ RANTES (Catalog # 3819-FR) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Feline CCL5/ RANTES (80 ng/mL) is neutralized (green line) by increasing concentrations of Sheep Anti-Feline CCL5/RANTES Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3819). The ND50 is typically 0.5‑2.5 µg/mL.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta -chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1‑3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature feline CCL5 shares 84% aa seqeuence identity with canine CCL5 and 71%‑75% with cotton rat, human, mouse, and rat CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11‑13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14‑16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17).
Schall, T.J. et al. (1990) Nature 347:669.
Bacon, K.B. et al. (1995) Science 269:1727.
Fischer, F.R. et al. (2001) J. Immunol. 167:1637.
Schall, T.J. et al. (1992) Eur. J. Immunol. 22:1477.
Kimura, T. et al. (2003) Vet. Dermatol. 14:269.
Appay, V. and S.L. Rowland-Jones (2001) Trends Immunol. 22:83.
Levy, J.A. (2009) J. Immunol. 182:3945.
Randolph-Habecker, J.R. et al. (2002) Cytokine 19:37.
DeVico, A.L. and Gallo, R.C. (2004) Nat. Rev. Microbiol. 2:401.
Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
Appay, V. et al. (1999) J. Biol. Chem. 274:27505.
Proudfoot, A.E.I. et al. (2003) Proc. Natl. Acad. Sci. 100:1885.
von Hundelshausen, P. et al. (2005) Blood 105:924.
von Hundelshausen, P. et al. (2001) Circulation 103:1772.
Zernecke, A. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1897.
Baltus, T. et al. (2003) Blood 102:1985.
Soria, G. and A. Ben-Baruch (2008) Cancer Lett. 267:271.
CCL5; chemokine (C-C motif) ligand 5; D17S136Enormally T-expressed, and presumably secreted; EoCP; Eosinophil chemotactic cytokine; RANTES; SISd; SIS-delta; small inducible cytokine A5 (RANTES); small inducible cytokine subfamily A (Cys-Cys), member 5; Small-inducible cytokine A5; T cell-specific protein P228; T-cell specific protein p288; TCP228T-cell-specific protein RANTES
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.